Biomea Fusion, Inc. (BMEA)
NASDAQ: BMEA · Real-Time Price · USD
2.295
+0.235 (11.41%)
Apr 24, 2025, 4:00 PM EDT - Market closed
Company Description
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases.
It’s lead product candidate is icovamenib, is designed to be a bioavailable, potent, and covalent inhibitor of menin, a ubiquitously expressed scaffold protein that functions in histone modification and epigenetic gene regulation to impact multiple cellular processes including cell cycle control, apoptosis, and DNA damage repair, it is used for the treatment of menin regulated or dependent diseases such as type 1 and type 2 diabetes.
The company was incorporated in 2017 and is headquartered in Redwood City, California.
Biomea Fusion, Inc.
| Country | United States |
| Founded | 2017 |
| IPO Date | Apr 16, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 106 |
| CEO | Michael J. Hitchcock |
Contact Details
Address: 900 Middlefield Road, 4th Floor Redwood City, California 94063 United States | |
| Phone | 650 980 9099 |
| Website | biomeafusion.com |
Stock Details
| Ticker Symbol | BMEA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001840439 |
| CUSIP Number | 09077A106 |
| ISIN Number | US09077A1060 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Michael J. M. Hitchcock Ph.D. | Interim Chief Executive Officer and Director |
| Ramses M. Erdtmann | Co-Founder, President, Chief Operating Officer and Director |
| Dr. Juan Pablo Frias M.D. | Chief Medical Officer |
| Heow Tan | Chief Technology and Quality Officer |
| Naomi Cretcher | Chief People Officer |
| Dr. Thorsten Kirschberg Ph.D. | Executive Vice President of Chemistry |
| Dr. Stephan Morris M.D. | Chief Development Officer |
| Ravi Upasani | Executive Vice President of Intellectual Property |
| Caroline Perez- Dupont | Senior Vice President of Contracts |
| Dr. Alex Cacovean | Vice President of Clinical Development and Clinical Sciences |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 18, 2025 | PRE 14A | Other preliminary proxy statements |
| Mar 31, 2025 | 10-K | Annual Report |
| Mar 31, 2025 | 8-K | Current Report |
| Mar 27, 2025 | 8-K | Current Report |
| Feb 28, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Jan 15, 2025 | 8-K | Current Report |
| Jan 6, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Dec 20, 2024 | 8-K | Current Report |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |